MBRX -
Moleculin Biotech, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 0.42 0.01 (3.56%) |
--- |
--- |
0.0 (-0.81%) |
0.01 (1.37%) |
0.01 (2.26%) |
0.01 (2.92%) |
0.0 (-1.01%) |
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Earnings & Ratios
- Basic EPS:
- -0.49
- Diluted EPS:
- Basic P/E:
- -0.8776
- Diluted P/E:
- RSI(14) 1m:
- 43.21
- VWAP:
- 0.43
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Dec 04, 2025 18:00
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Jun 04, 2025 12:45
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Mar 11, 2025 12:45
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Mar 03, 2025 13:30
Moleculin Participates in Virtual Investor "What This Means" Segment
Jan 27, 2025 13:30
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
Jan 08, 2025 13:30
Bitget Wallet Expands DeSci Ecosystem Access
Dec 26, 2024 14:54
Moleculin Participates in Virtual Investor "What this Means" Segment
Sep 16, 2024 12:30
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
Sep 09, 2024 12:15
Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday
Mar 20, 2024 06:44